Similarly, astegolimab was an anti-ST2 antibody which was being investigated for the treatment of moderate-to-severe AD, but it failed to meet its phase 2 trial primary endpoint (reduction in EASI relative to placebo at week 16) [177]. The gene discussed is IL1RL1; the disease is Alzheimer disease.